Credit Suisse Ag Protalix Bio Therapeutics, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.81 - $1.33 $25,898 - $42,525	-31,974 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$1.31 - $1.87 $44,475 - $63,488	-33,951 Reduced 51.5%	31,974 $43,000
Q2 2021 Aug 16, 2021	BUY	$1.86 - $6.22 $104,020 - $347,853	55,925 Added 559.25%	65,925 $126,000
Q1 2021 May 14, 2021	BUY	$3.58 - $6.45 $35,800 - $64,500	10,000 New	10,000 $45,000
Q3 2020 Nov 13, 2020	SELL	$3.37 - $3.93 $33,700 - $39,300	-10,000 Closed	0 $0

Q2 2020 Aug 12, 2020	BUY	$2.19 - $4.5 $21,900 - $45,000	10,000 New	10,000 $38,000

9.27M

40.6K

10.1K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $53.7M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.